Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Infinium PharmachemNSE:INFINIUM +0.57%87 Days Payable is 23.35 as of Mar. 2026, which is 45% below its 10-year median of 42.23. GuruFocus rates NSE:INFINIUM with a GF Score™ of 87/100 and a GF Value™ of ₹305.70 (Significantly Undervalued). The stock has 2 warning signs investors should review. Among 1,554 Chemicals companies, Infinium Pharmachem ranks worse than 82.18% on this metric.
The historical rank and industry rank for Infinium Pharmachem's Days Payable or its related term are showing as below:
NSE:INFINIUM'
s Days Payable Range Over the Past 10 Years
Min: 20.07 Med: 42.23 Max: 82.28
Current: 27.96
During the past 7 years, Infinium Pharmachem's highest Days Payable was 82.28. The lowest was 20.07. And the median was 42.23.
NSE:INFINIUM's Days Payable is ranked worse than 82.18% of 1554
companies
in the Chemicals industry
Industry Median: 59.565
vs NSE:INFINIUM: 27.96
Infinium Pharmachem's Days Payable
declined
from Mar. 2025 (40.59) to Mar. 2026 (23.35).
It may suggest that Infinium Pharmachemaccelerated paying its suppliers.
Infinium Pharmachem Days Payable Related Terms
Infinium Pharmachem Days Payable Historical Data
* Premium members only.
The historical data trend for Infinium Pharmachem's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Chemicals subindustry, Infinium Pharmachem's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Infinium Pharmachem Days Payable vs Chemicals Industry
For the Chemicals industry and Basic Materials sector, Infinium Pharmachem's Days Payable distribution charts can be found below:
* The bar in red indicates where Infinium Pharmachem's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Infinium Pharmachem's Days Payable for the fiscal year that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Infinium Pharmachem (NSE:INFINIUM) has a Days Payable of 23.35 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Infinium Pharmachem and its competitors. This is 45% below median its historical median of 42.23. Over the past decade, Infinium Pharmachem's Days Payable has ranged from 20.07 to 82.28. According to the industry distribution chart, Infinium Pharmachem ranks #1277 out of 1554 companies in the Chemicals industry, placing it in the top 82.2%.
Is Infinium Pharmachem's Days Payable too high?
Infinium Pharmachem's current Days Payable of 23.35 is 45% below median its 10-year median of 42.23. Over the past 10 years, this metric has ranged from a low of 20.07 to a high of 82.28. The Chemicals industry median Days Payable is 59.57. Infinium Pharmachem's value of 23.35 is 60.8% below this industry median. Based on the distribution chart, Infinium Pharmachem ranks #1277 out of 1554 companies in the Chemicals industry, which is in the bottom quartile relative to peers. Overall, Infinium Pharmachem has a GF Score™ of 87/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Infinium Pharmachem's Days Payable compare to DOW?
According to the Chemicals industry distribution chart, Infinium Pharmachem ranks #1277 out of 1554 companies for Days Payable. This places Infinium Pharmachem in the lower half of its industry. The industry median Days Payable is 59.57. Infinium Pharmachem's value of 23.35 is 60.8% below this benchmark. Historically, Infinium Pharmachem's own Days Payable has ranged from 20.07 to 82.28 over the past decade. While the company's 10-year median is 42.23 vs. the industry median of 59.57, Infinium Pharmachem has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Chemicals company?
The median Days Payable among Chemicals companies is 59.57, based on 1,554 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Infinium Pharmachem's current Days Payable of 23.35 is 60.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Infinium Pharmachem and its competitors. For the Chemicals industry, the median Days Payable is 59.57 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Infinium Pharmachem's current Days Payable is 23.35, which is 45% below median its own 10-year median of 42.23. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Infinium Pharmachem stock overvalued right now?
Based on GuruFocus' analysis, Infinium Pharmachem (NSE:INFINIUM) is currently considered Significantly Undervalued. The stock's GF Value™ is ₹305.70, compared to a current price of ₹210.70 — trading 31.1% below its estimated fair value. The current Days Payable is 23.35, which is 45% below median its 10-year median of 42.23 and 60.8% below the Chemicals industry median of 59.57. Infinium Pharmachem's overall GF Score™ is 87/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Infinium Pharmachem (NSE:INFINIUM), the current Days Payable is 23.35 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Infinium Pharmachem (NSE:INFINIUM) Overvalued in 2026?
Based on GuruFocus' analysis, Infinium Pharmachem stock appears to be undervalued.
The current stock price of ₹210.70 is trading 31.1% below its estimated GF Value™ of ₹305.70.
GuruFocus considers Infinium Pharmachem to be Significantly Undervalued.
Key valuation signals for NSE:INFINIUM:
Days Payable: 23.35 (45% below median its 10-year median of 42.23)
GF Value™: ₹305.70 vs. price of ₹210.70 (31.1% below fair value)
Industry Position: 60.8% below the Chemicals median (#1277 of 1554)
No single metric tells the full story. See the NSE:INFINIUM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Infinium Pharmachem Ltd is engaged in the business of manufacturing and supplying Iodine, Iodine Derivatives and Active Pharmaceutical Ingredients (APIs). It provides fully integrated customized services from R & D to Commercial scale manufacturing and packaging for its products to the Pharmaceutical, Agrochemical, Nutraceutical, Speciality Chemicals and various other chemicals Industries.
87GF Score
Get the complete analysis for NSE:INFINIUM
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:INFINIUM has been successfully added to your 
